ArticleInternational journal of molecular sciences2025
Longitudinal Evaluation of the Detection Potential of Serum Oligoelements Cu, Se and Zn for the Diagnosis of Alzheimer's Disease in the 3xTg-AD Animal Model.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sexual dimorphism and photoperiodism in cognitive and neuronal ionic changes in scopolamine-induced cognitive impairment.Metabolic brain disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of β-amyloid (Aβ) and hyperphosphorylated tau, leading to neuroinflammation, oxidative stress, and neuronal death. Early detection of AD remains a challenge, as clinical manifestations only emerge in the advanced stages, limiting therapeutic interventions. Minimally invasive biomarkers are essential for early identification and monitoring of disease progression. This study aims to evaluate the sensitivity of the relationship between serum oligoelement levels as biomarkers and the monitoring of AD progression in the 3xTg-AD model. Transgenic 3xTg-AD mice and C57BL/6 controls were evaluated over 12 months through serum oligoelement quantification using inductively coupled plasma mass spectrometry (ICP-MS), Aβ deposition via immunohistochemistry, and cognitive assessments using memory tests (Morris water maze and novel object recognition test), as well as spontaneous locomotion analysis using the open field test. The results demonstrated that oligoelements (copper, zinc, and selenium) were sensitive in detecting alterations in the AD group, preceding cognitive and motor deficits. Immunohistochemistry was performed for qualitative purposes, confirming the presence of β-amyloid in the CNS of transgenic animals. Up to the third month, labeling was moderate and restricted to neuronal cell bodies; from the fifth month onward, evident extracellular deposits emerged. Behavioral assessment indicated impairments in spatial and episodic memory, as well as altered locomotor patterns in AD mice. These findings reinforce that oligoelement variations may be associated with neurodegenerative processes, including oxidative stress and synaptic dysfunction. Thus, oligoelement analysis emerges as a promising approach for the early diagnosis of AD and the monitoring of disease progression, potentially contributing to the development of new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.